The use of base editing to generate universal off-the-shelf CAR T cells induced durable remissions -- up to 36 months in one ...

Data presented at ASH 2025 suggest earlier-line use of cilta-cel leads to better outcomes in multiple myeloma because patients have fitter immune systems and less exhausted T cells, improving CAR T ...

CAR-T therapy is a major advance in cancer care, but high costs and centralized global manufacturing limit access.

A neuroblastoma patient treated with CAR T-cell therapy as a child achieved a complete response and remains in remission more than 18 years later. Researchers suggest this is the longest reported ...

The EVEREST-2 study reported the first complete response to CAR-T cell therapy in a non-small cell lung cancer patient.

A blood cancer diagnosis comes with a lot of new information and confusion ranging from blood tests and medical terminology to healthcare provider conversations and treatment considerations. Here’s ...

CAR-T cell therapy provides long, treatment-free remissions for relapsed multiple myeloma, using genetically modified T cells ...

Improved QOL is observed in patients over two years post-infusion and those without disease progression, highlighting the ...

The Cellares Cell Shuttle platform was the first to receive the FDA’s Advanced Manufacturing Technology (AMT) designation, which offers partners additional touchpoints and priority review mechanisms ...

An Arizona patient with synovial sarcoma has received a new immune cell therapy. Officials at HonorHealth Research Institute ...

Rybrevant Faspro, the new subcutaneous version of amivantamab, was approved for patients with a specific form of lung cancer ...